+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compounds in clinical Phase III and beyond



Compounds in clinical Phase III and beyond



Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 180: 137-163



Targeted therapies against cancer have become more and more important. In particular, the inhibition of tumor angiogenesis and vascular targeting have been the focus of new treatment strategies. Numerous new substances were developed as angiogenesis inhibitors and evaluated in clinical trials for safety, tolerance, and efficacy. With positive study results, some of these molecules have already been approved for clinical use. For example, this is true for the vascular endothelial growth factor neutralizing antibody bevacizumab (BEV) in metastatic colorectal cancer, nonsmall cell lung cancer, renal cancer, and breast cancer. The tyrosine kinase (TK) inhibitors sorafenib and sunitinib have been approved for metastatic renal cancer as well as for hepatocellular carcinoma, and sunitinib has also been approved for gastrointestinal stroma tumors. In this chapter we try to give an overview of the substances currently investigated in Phase III studies and beyond with regard to antiangiogenesis in cancer therapy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052269429

Download citation: RISBibTeXText

PMID: 20033382


Related references

Antimalarial compounds in Phase II clinical development. Expert Opinion on Investigational Drugs 24(3): 363-382, 2015

Structure and phase stability of binary zintl-phase compounds: lithium-group 13 intermetallics and metal-doped group 14 clathrate compounds. Chemistry 8(12): 2787-2798, 2002

Estimating gas phase rate constants for reactions of organic compounds with hydroxyl radicals from relative rates measured in 1 1 2 trichloro 1 2 2 trifluoroethane solution a method for estimating the tropospheric persistence of compounds difficult to study in the gas phase. Abstracts of Papers American Chemical Society 192, 1986

Review of new challenges for the development of early phase biologic compounds in the wake of the TGN 1412 clinical trial. 2007

Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials. Journal of Cellular Biochemistry. Supplement 19: 94-98, 1994

The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study". Alzheimer Disease and Associated Disorders 9(3): 139-145, 1995

Clinical experiences with the sulfonylurea compounds In The effects of the sulfonylureas and related compounds in experimental and clinical diabetes. Ann New York Acad Sci: 233-238, 1957

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chemical Reviews 116(2): 422-518, 2016

Tandem mass spectrometry with online high-flow reversed-phase extraction and normal-phase chromatography on silica columns with aqueous-organic mobile phase for quantitation of polar compounds in biological fluids. Rapid Communications in Mass Spectrometry 19(20): 2929-2934, 2005

The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. Journal of Cellular Biochemistry. Supplement 19: 283-289, 1994

Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 5(4): 192-194, 1992

A comparison of DNA binding profiles of bis platinum compounds with polyamine linkers and a trinuclear platinum Phase I clinical agent. Proceedings of the American Association for Cancer Research Annual Meeting (41): 264, 2000

Separation and characterization of phenolic compounds and triterpenoid saponins in licorice (Glycyrrhiza uralensis) using mobile phase-dependent reversed-phase×reversed-phase comprehensive two-dimensional liquid chromatography coupled with mass spectrometry. Journal of Chromatography. a 1402: 36-45, 2015

A comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase II clinical agent BBR3464. Journal of Biological Inorganic Chemistry 7(4-5): 397-404, 2002

Determination of organic and inorganic mercury compounds by reverse-phase high-performance liquid chromatography after extraction of the compounds as their dithizonates. Analytica Chimica Acta 185: 249-258, 1986